How much is the current price of the Indian version of Encorafenib?
Currently, the Indian version of canafenib (Encorafenib) is not officially sold in the Indian market. Therefore, if patients want to purchase canafenib generics through Indian channels, they need to pay attention to whether the generics are certified and have reliable suppliers. Currently, the generic drugs of Canafenib available on the market are mainly Lao versions, and no generic drugs produced in India have entered the market. The price of the Lao version of Canafenib generic drug is about 4,000 yuan, which is relatively affordable.
The original drug of Canafenib is mainly sold in the European market, and the price is relatively high. Taking the European version as an example, the price per box of 75mg42 capsules may reach more than 10,000 yuan, while the price of the larger specification 75mg*168 capsules may reach more than 40,000 yuan. This price range is mainly affected by exchange rate fluctuations, so patients may experience different prices if purchasing from overseas.

Due to the higher prices of original drugs, many patients choose generic drugs to reduce financial pressure. The ingredients of the Laotian version of the generic version of Canafenib are similar to the original drug, and the efficacy is basically the same. The price is much lower than the original drug, about 4,000 yuan per box. This makes long-term treatment more affordable for many patients, especially cancer patients who often require long-term use of targeted drugs.
Although the Indian version of canafenib has not yet been launched, India, as one of the world's major generic drug production bases, has mature drug production capabilities. If a generic version of canafenib is launched in the Indian market in the future, it is expected that its price will be more competitive than the original drug and the Lao version of the generic version, which may be around a few thousand yuan. Patients can look forward to obtaining more cost-effective generic versions of canafenib from Indian sources in the future.
Reference materials:https://www.braftovi.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)